10.09.2021 • News

Kemira Hikes China ASA Capacity

Following the start of pre-engineering in May, Kemira has confirmed that it is adding extra production capacity for alkenyl succinic anhydride (ASA) sizing agent in China. The Finnish company is making a multi-million investment in a third production line at its site in Nanjing, Jiangsu province – it did not disclose capacity details.

Kemira is the leading producer and supplier of ASA in the Asia-Pacific region. We are committed to the industry and want to ensure security of supply and high-quality products in the long term, supporting our customers’ expansion plans. The capacity ramp-up will take place during 2022-2023,” said Alexander Wahl, director of the global sizing product line.

The company added that the decision to expand comes at a time when customers are concerned about current tight supply coupled with rapidly growing demand for the chemical, which is used to improve water-resistance in paper and packaging board.

In May, Kemira announced the start-up of a new dry polymer production plant in Ulsan, South Korea, which is run as a joint venture with Yongsan Chemicals. The facility produces dry polyacrylamide products, mostly for retention and drainage applications that Kemira said are critical in modern, fast paper and board production. 

Author: Elaine Burridge, Freelance Journalist

 

Following the start of pre-engineering in May, Kemira has confirmed it is...
Following the start of pre-engineering in May, Kemira has confirmed it is adding extra capacity for alkenyl succinic anhydride sizing agent in China. The company is making a multi-million investment in a third line in Nanjing, where the new capacity will ramp up during 2022-2023. (c) Kemira

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read